Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Immunotech Biopharm Ltd
6978Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for non-hodgkin lymphoma; and TCR-T cell series products to treat solid tumors. Further, the company's pre-clinical products include aT19 to treat acute lymphoblastic leukaemia; CAR-T-43 for T cell leukaemia and T cell lymphoma; CAR-T-22 for B lymphocyte leukaemia; CAR-T-BCMA to treat multiple myeloma; CAR-T-ENX for solid tumors; TCR800 to treat renal cancer; and EBV, CMV specific T cells for EBV/CMV infection. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China. Address: Guosheng Technology Park, Beijing, China
Analytics
Preço Alvo de Wall Street
154.18 HKDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 6978
Análise de Dividendos 6978
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos 6978
Avaliação de ações 6978
Relatório 6978
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |